Agenus to Provide Corporate Update and Second Quarter 2022 Financial Report
27 Juli 2022 - 02:30PM
Agenus (NASDAQ: AGEN) an immuno-oncology company with an extensive
pipeline of therapeutics designed to activate the immune response
to cancers and infections, today announced it will release its
second quarter 2022 financial results before the market opens on
Tuesday, August 9, 2022. Agenus executives will host a conference
call and webcast at 8:30 a.m. ET that morning to discuss the
results and to provide a corporate update.
Conference CallDial-in numbers: (646) 307-1963
(US-NY) or (800) 715-9871 (US & CA)Event ID: 6683845
WebcastA webcast and replay of the conference
call will be accessible from the Events & Presentations page of
the Company’s website
at https://investor.agenusbio.com/events-and-presentations and
via https://edge.media-server.com/mmc/p/xh3u6boi.
About AgenusAgenus is a clinical-stage
immuno-oncology company focused on the discovery and development of
therapies that engage the body's immune system to fight cancer and
infections. The Company's vision is to expand the patient
populations benefiting from cancer immunotherapy by pursuing
combination approaches that leverage a broad repertoire of antibody
therapeutics, adoptive cell therapies (through its subsidiary MiNK
Therapeutics), and adjuvants (through its subsidiary SaponiQx). The
Company is equipped with a suite of antibody discovery platforms
and a state-of-the-art GMP manufacturing facility with the capacity
to support clinical programs. Agenus is headquartered in Lexington,
MA. For more information, please visit www.agenusbio.com and our
Twitter handle @agenus_bio. Information that may be important to
investors will be routinely posted on our website and Twitter.
ContactAgenus Inc.Ethan
LovellChief External Affairs & Communications
Officer339-927-1763ethan.lovell@agenusbio.com
Agenus (NASDAQ:AGEN)
Historical Stock Chart
Von Feb 2024 bis Mär 2024
Agenus (NASDAQ:AGEN)
Historical Stock Chart
Von Mär 2023 bis Mär 2024